FDA in­spec­tion un­cov­ers cher­ry-col­ored an­tibi­ot­ic residue on equip­ment at Teva's New Jer­sey site

An FDA in­spec­tion re­port on Te­va’s man­u­fac­tur­ing site in New Jer­sey has re­vealed is­sues with both equip­ment clean­ing and qual­i­ty.

The three-page re­port, which was ob­tained by End­points News via a FOIA re­quest from the FDA, showed sev­er­al ob­ser­va­tions from its in­spec­tion, which took place be­tween Nov. 1 and Nov. 10 of last year, at Te­va’s site in Fair­field, NJ.

In­spec­tors not­ed a buildup of “un­known residue” with­in two pro­duc­tion rooms that had been doc­u­ment­ed as cleaned. Specif­i­cal­ly, a pink- or red-col­ored residue was found on equip­ment in the mix­ing room that had most re­cent­ly been used to man­u­fac­ture Ce­fadrox­il tablets. Ce­fadrox­il, which is used to treat bac­te­r­i­al in­fec­tions in var­i­ous parts of the body, does not use any dyes or fla­vor­ings.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER